manilatimes4 分钟
Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest ...
At Week 14, 69% (71% of b/tsDMARD-naïve and 66% of b/tsDMARD-experienced) or 220 of the 318 rosnilimab-treated patients across all doses achieved CDAI LDA and were eligible to remain on continued ...
Raymond James raises INmune Bio stock target to $23
James increased the price target for INmune Bio Inc. (NASDAQ: NASDAQ:INMB) shares to $23 from the previous $18, while maintaining an Outperform rating. According to InvestingPro data, the stock ...